Tag
MSI-H/dMMR gastroesophageal adenocarcinoma showed high response rates to immune checkpoint inhibitors, including durable complete responses in locoregional disease that may support carefully selected nonoperative management.
This single-center cohort found high and durable checkpoint inhibitor responses in dMMR/MSI-H gastroesophageal adenocarcinoma, including complete responses in locoregional disease that may support carefully selected nonoperative management.
Marengo Therapeutics reports promising Phase 2 results for invikafusp alfa, showing significant tumor shrinkage and disease control in advanced solid tumors with high mutation burden or MSI-H/dMMR.
Neoadjuvant PD-1 blockade with dostarlimab enabled organ preservation and high recurrence-free survival in early-stage mismatch repair–deficient (dMMR) solid tumors, extending nonoperative management beyond rectal cancer.
